SRC and cancer: Indeed, TFF3 acts as a promiscuous activator of multiple survival pathways in cancer cells, including HER1-4, PI3K/AKT, RAS/MEK/MAPK, and cSRC/STAT3, which are critically associated with enhanced cancer cell survival, metastasis, and resistance to therapy8,11–18.